PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980181
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980181
The global joint pain injections market was valued at USD 6.34 billion in 2025 and is projected to grow to USD 6.97 billion in 2026, reaching USD 15.67 billion by 2034, reflecting a CAGR of 10.70% during the forecast period. North America led the market in 2025 with a 45.52% share, driven by a high prevalence of osteoarthritis, advanced healthcare infrastructure, and favorable reimbursement policies. The U.S. joint pain injection market is projected to reach USD 5.49 billion by 2032, fueled by rising sports injuries and increasing awareness of joint disorders.
Joint pain injections are widely used for managing pain and inflammation in patients with musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. Corticosteroid injections are the first line of treatment, delivered directly to affected joints. The growing prevalence of musculoskeletal conditions and the focus of key players on developing novel therapies are key drivers of market growth.
During the COVID-19 pandemic, market growth declined due to reduced patient visits. However, post-pandemic recovery has been observed, supported by increasing awareness of musculoskeletal conditions and continuous introduction of innovative products.
Market Trends
The market is witnessing a shift toward minimally invasive procedures such as platelet-rich plasma (PRP) injections, hyaluronic acid (HA) injections, and plasma matrix therapy. These procedures provide rapid drug absorption, prolonged pain relief, and less discomfort, resulting in growing patient preference.
For instance, in August 2021, Bioventus invested in Trice Medical, Inc. to expand minimally invasive technologies for orthopedic procedures. Ongoing research, such as the phase 3 clinical trials conducted by Emory University (2022) using Mesenchymal Stem Cells (MSC) and Bone Marrow Concentrate (BMAC) for knee osteoarthritis, underscores the increasing adoption of innovative treatments.
Market Growth Factors
Restraining Factors
High costs and limited access in emerging countries restrict adoption. For example, PRP injections in the U.S. cost around USD 500-2,000 per injection, requiring multiple doses for efficacy. Alternative treatments, such as physical therapy or oral medications, offer lower-cost solutions, limiting market growth in developing regions.
Market Segmentation
By Product:
By Joint Type:
By Distribution Channel:
Key Market Players
Major players include Bioventus, SEIKAGAKU CORPORATION, Zimmer Biomet, Anika Therapeutics, Sanofi, Pacira BioSciences, Teva Pharmaceutical, Ferring B.V., and Dr. Reddy's Laboratories. Companies focus on R&D, new product launches, and strategic partnerships to increase market share.
Industry Developments:
Conclusion
The joint pain injections market is set to grow from USD 6.34 billion in 2025 to USD 15.67 billion by 2034, at a 10.70% CAGR, driven by increasing musculoskeletal disorders, sports injuries, awareness of minimally invasive procedures, and innovative product launches. North America remains the largest market, while Asia Pacific shows the fastest growth due to demographic shifts. Despite challenges like high costs and limited access in emerging markets, continuous technological innovation and expanding distribution channels are poised to propel market growth throughout the forecast period.
Segmentation By Product
By Joint Type
By Distribution Channel
By Geography